Coronary disease & ACS

Prognostic Relevance of Type 4a Myocardial Infarction and Periprocedural Myocardial Injury in Patients With Non–ST-Segment–Elevation Myocardial Infarction

CirculationPublished Prospective cohort study

Authors' conclusion

Periprocedural ischemic events were frequent in patients with NSTEMI undergoing PCI with prognostic implications. A post-PCI ΔcTnI >40%, combined with an absolute postprocedural value of ≥5 times the 99th percentile upper reference limit, was identified as the optimal threshold for diagnosing prognostically relevant PMI.

Study context

Population
Consecutive patients with NSTEMI undergoing percutaneous coronary intervention (PCI) with stable or falling pre-PCI cardiac troponin I (cTnI), January 2017 to April 2022validation cohort n = 305
Participants
1,412 patients
Exposure
Periprocedural myocardial injury (PMI) with type 4a myocardial infarction (MI) vs PMI without type 4a MI vs no PMI
  • PMI with type 4a MIn = 240
  • PMI without type 4a MIn = 288
  • No PMIn = 884reference
Outcome
All-cause mortality
Follow-up
1 year
Methodological detailsconsecutive patients, internal validation cohort
  • Consecutive patients
  • Internal validation cohort

Main finding

As reported in the abstract

1-year all-cause mortality

Incidence

Observational data: associations, not effects.

Secondary outcomes

MACE at 1 year

Type 4a MI had the highest 1-year MACE rate

Optimal post-PCI ΔcTnI threshold for prognostically relevant PMI

Optimal threshold for prognostically relevant PMI, confirmed in internal validation cohort (n = 305)
>40%
ΔcTnI >20% but ≤40% showed outcomes similar to no PMI

Original publication

Prognostic Relevance of Type 4a Myocardial Infarction and Periprocedural Myocardial Injury in Patients With Non–ST-Segment–Elevation Myocardial Infarction. Circulation. Published 19 February 2025. doi:10.1161/circulationaha.124.070729

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.